Post-approval studies (Phase 4)Ended earlyNCT02570789
What this trial is testing
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
Who this might be right for
Clear-cell Metastatic Renal Cell Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 90